Browsing tag:


Lenalidomide created quite a stir on Wall Street on July 11, 2013 when shares of Celgene’s Revlimid, the brand name of Lenalidomide, soared. The frenzy occurred after Celgene released data from the Phase 3 study of Lenalidomide, revealing  the great success of this blood cancer drug. Lenalidomide proved in Phase 3 studies to effectively halt[…]

Read More

The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007.  Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]

Read More

For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service